- Home
- GGZ vs RAPT Comparison
GGZ vs RAPT Comparison
Compare GGZ & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GGZ
- RAPT
- Stock Information
- Founded
- GGZ 2013
- RAPT 2015
- Country
- GGZ United States
- RAPT United States
- Employees
- GGZ N/A
- RAPT N/A
- Industry
- GGZ Investment Managers
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- GGZ Finance
- RAPT Health Care
- Exchange
- GGZ Nasdaq
- RAPT Nasdaq
- Market Cap
- GGZ 105.1M
- RAPT 117.5M
- IPO Year
- GGZ N/A
- RAPT 2019
- Fundamental
- Price
- GGZ $12.62
- RAPT $7.35
- Analyst Decision
- GGZ
- RAPT Buy
- Analyst Count
- GGZ 0
- RAPT 5
- Target Price
- GGZ N/A
- RAPT $42.00
- AVG Volume (30 Days)
- GGZ 12.8K
- RAPT 120.8K
- Earning Date
- GGZ 01-01-0001
- RAPT 08-07-2025
- Dividend Yield
- GGZ 5.39%
- RAPT N/A
- EPS Growth
- GGZ N/A
- RAPT N/A
- EPS
- GGZ 1.75
- RAPT N/A
- Revenue
- GGZ N/A
- RAPT N/A
- Revenue This Year
- GGZ N/A
- RAPT N/A
- Revenue Next Year
- GGZ N/A
- RAPT N/A
- P/E Ratio
- GGZ $6.79
- RAPT N/A
- Revenue Growth
- GGZ N/A
- RAPT N/A
- 52 Week Low
- GGZ $9.43
- RAPT $5.67
- 52 Week High
- GGZ $12.50
- RAPT $30.60
- Technical
- Relative Strength Index (RSI)
- GGZ 53.61
- RAPT 43.57
- Support Level
- GGZ $12.80
- RAPT $6.88
- Resistance Level
- GGZ $13.16
- RAPT $8.91
- Average True Range (ATR)
- GGZ 0.22
- RAPT 0.70
- MACD
- GGZ -0.06
- RAPT -0.16
- Stochastic Oscillator
- GGZ 27.59
- RAPT 11.36
About GGZ Gabelli Global Small and Mid Cap Value Trust (The) of Beneficial Interest
The Gabelli Global Small and Mid Cap Value Trust is a diversified closed-ended management investment company whose investment objective is long-term capital growth. It invests in equity securities such as common stock and preferred stock of companies.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.